9MSD の概要
| エントリーDOI | 10.2210/pdb9msd/pdb |
| EMDBエントリー | 48575 |
| 分子名称 | 001428_T278M_L14 SOSIP gp140, G002-293-0536 Fab heavy chain, G002-293-0536 Fab light chain, ... (8 entities in total) |
| 機能のキーワード | g002, clinical trial, hiv-1, vrc01, human antibody, vaccine, env, viral protein, viral protein-immune system complex, viral protein/immune system |
| 由来する生物種 | Human immunodeficiency virus 1 詳細 |
| タンパク質・核酸の鎖数 | 15 |
| 化学式量合計 | 509483.33 |
| 構造登録者 | |
| 主引用文献 | Willis, J.R.,Prabhakaran, M.,Muthui, M.,Naidoo, A.,Sincomb, T.,Wu, W.,Cottrell, C.A.,Landais, E.,deCamp, A.C.,Keshavarzi, N.R.,Kalyuzhniy, O.,Lee, J.H.,Murungi, L.M.,Ogonda, W.A.,Yates, N.L.,Corcoran, M.M.,Phulera, S.,Musando, J.,Tsai, A.,Lemire, G.,Sein, Y.,Muteti, M.,Alamuri, P.,Bohl, J.A.,Holman, D.,Himansu, S.,Leav, B.,Reuter, C.,Lin, L.A.,Ding, B.,He, C.,Straus, W.L.,MacPhee, K.J.,Regadas, I.,Nyabundi, D.V.,Chirchir, R.,Anzala, A.,Kimotho, J.N.,Kibet, C.,Greene, K.,Gao, H.,Beatman, E.,Benson, K.,Laddy, D.,Brown, D.M.,Bronson, R.,Baptiste, J.,Gajjala, S.,Rikhtegaran-Tehrani, Z.,Benner, A.,Ramaswami, M.,Lu, D.,Alavi, N.,Amirzehni, S.,Kubitz, M.,Tingle, R.,Georgeson, E.,Phelps, N.,Adachi, Y.,Liguori, A.,Flynn, C.,McKenney, K.,Zhou, X.,Owuor, D.C.,Owuor, S.,Kim, S.Y.,Duff, M.,Kim, J.Y.,Gibson, G.,Baboo, S.,Diedrich, J.,Schiffner, T.,Shields, M.,Matsoso, M.,Santos, J.,Syvertsen, K.,Kennedy, A.,Schroeter, M.,Vekemans, J.,Yates, J.,Paulson, J.C.,Hyrien, O.,McDermott, A.B.,Maenetje, P.,Nyombayire, J.,Karita, E.,Ingabire, R.,Edward, V.,Muturi-Kioi, V.,Maenza, J.,Shapiro, A.E.,McElrath, M.J.,Edupuganti, S.,Taylor, B.S.,Diemert, D.,Ozorowski, G.,Koup, R.A.,Montefiori, D.,Ward, A.B.,Hedestam, G.K.,Tomaras, G.,Hunt, D.J.,Muema, D.,Sok, D.,Laufer, D.S.,Andrews, S.F.,Nduati, E.W.,Schief, W.R. Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans. Science, :eadr8382-eadr8382, 2025 Cited by PubMed Abstract: A leading HIV vaccine strategy requires a priming immunogen to induce broadly neutralizing antibody (bnAb) precursors, followed by a series of heterologous boosters to elicit somatic hypermutation (SHM) and produce bnAbs. In two randomized, open-label phase 1 human clinical trials, IAVI-G002 in the United States and IAVI-G003 in Rwanda and South Africa, we evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens (both trials) and first-boosting immunogens (IAVI-G002). The vaccines were generally safe and well tolerated, except 18% of IAVI-G002 participants experienced skin reactions. Priming induced bnAb precursors with substantial frequencies and SHM, and heterologous boosting elicited increased SHM, affinity, and neutralization activity toward bnAb development. The results establish clinical proof of concept that heterologous boosting can advance bnAb-precursor maturation and demonstrate bnAb priming in Africa where the HIV burden is highest. PubMed: 40373112DOI: 10.1126/science.adr8382 主引用文献が同じPDBエントリー |
| 実験手法 | ELECTRON MICROSCOPY (3.2 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
をダウンロード
